Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Strong Pipeline of mAbs Biosimilars in the US and Europe Lends Impetus to Global Market

Published: Tuesday, February 04, 2014
Last Updated: Tuesday, February 04, 2014
Bookmark and Share
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019.

The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth.

Already, Indian groups such as Dr. Reddy’s Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market.

Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term.

Biosimilar markets in countries such as the U.S. and Japan are also expected to grow exponentially with more clarity on the regulatory pathway.

New research from Frost & Sullivan’s ( Analysis of the Global Biosimilars Market finds the market earned revenue of about $1.2 billion in 2013 and estimates this to reach approximately $24 billion in 2019.

Untapped U.S. markets with a strong biosimilars pipeline as well as markets in Asia-Pacific and Latin America with a low cost of manufacturing will afford key growth opportunities.

“On one hand, the market is powering ahead regarding the strength of participants’ global expansion strategies, and, on the other, it is still beset by traditional patent-infringement issues,” said Frost & Sullivan Healthcare Senior Research Analyst K. Srinivas Sashidhar.

Sashidhar continued, “Moreover, the strategies adopted by innovator companies need to be taken into account. For instance, Johnson & Johnson has extended the European patent life of its innovator drug Remicade until February 2015, thereby delaying the launch of Hospira’s biosimilar monoclonal antibody (mAb) Inflectra and Celltrion’s biosimilar mAb Remsima.”

To further reduce the time to market, companies should also explore opportunities in mergers and acquisitions and alliances with companies having expertise in biosimilars manufacturing and development like Teva’s alliance with Cephalon and Lupin Pharmaceuticals’ alliance with Neuclone.

“In addition to mAbs, follitropins, interferons and low molecular weight heparins are likely to emerge in the long run,” added Sashidhar. “However, some companies may focus on specific therapeutic classes depending on their capabilities and strategic fit.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Disruptive Technologies Transforming the Growing Biologic Manufacturing Market
Single use technologies are paving the future of biopharmaceutical manufacturing.
Wednesday, June 22, 2016
Increased Public Private Partnerships to Drive Cutting Edge Innovation and Business Growth
Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself.
Thursday, October 08, 2015
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Monday, August 24, 2015
Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018.
Thursday, June 26, 2014
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.
Saturday, May 31, 2014
Emerging Technologies Redefine Infectious Disease Diagnostics
The largest opportunities lie in the developing regions of Asia, Africa and Latin America.
Wednesday, April 23, 2014
Drug Developers Drawn to Orphan Drugs Market
Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist.
Thursday, March 27, 2014
Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight
Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhea.
Thursday, March 27, 2014
Live Cell Imaging Revolutionizes Disease Diagnostics and Drug Discovery
Stakeholder collaboration will be crucial to convert these developments into clinically meaningful tests.
Friday, March 21, 2014
Automated Anatomic Pathology Labs Transform Global Tissue Diagnostics Market
Offering attractive procurement strategies will boost adoption of high-end tools.
Thursday, February 06, 2014
Predictions for the Global Chemicals, Materials and Food Industry
New insights based on Frost & Sullivan's ‘2013 Search for Growth’ survey.
Wednesday, December 11, 2013
CMOs Can Reduce Vendor Switching with Informational Marketing Efforts
Frost & Sullivan: Companies opt for CMOs offering high-quality services, confidentiality and clean regulatory track records.
Tuesday, November 26, 2013
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos